 The objective is to assess the efficacy and safety of 0.002 and 0.05 difluprednate ophthalmic emulsions in patients with postoperative inflammation after cataract surgery implantation of intraocular lens. In addition, the evaluation system for a future dose-finding phase III study of difluprednate ophthalmic emulsion will be established. 